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Background/aim: The aim of the study was to analyze the relationship of the immune response mediator genes’ polymorphic loci
(TNFA rs1800629, LTA rs909253, IL1B rs16944, IL2-IL21 rs6822844, IL2RA rs2104286, IL6 rs1800795, IL10 rs1800872, MIF rs755622,
CTLA4 rs3087243, NFKB1 rs28362491, PTPN22 rs2476601, PADI4 rs2240336) variants with the methotrexate efficacy in juvenile
idiopathic arthritis (JIA).
Materials and methods: The study included 274 JIA patients from the Republic of Bashkortostan, Russia. Achieving the American
College of Rheumatology Pediatric 30 (ACR Pedi 30) response was regarded as the presence of the response to methotrexate (otherwise,
as the absence), while achieving clinical remission on medication (Wallace et al., 2011) - as the sufficient response (otherwise, as the
insufficient). Genotyping was conducted by the real-time polymerase chain reaction.
Results: Associations with an altered risk of the nonresponse to methotrexate in JIA were observed for the alleles/genotypes of the loci
IL10 rs1800872 (in girls) and NFKB1 rs28362491 (in girls); with an altered risk of the insufficient response to methotrexate in JIA – for
the alleles/genotypes of the loci IL1B rs16944 (in boys), CTLA4 rs3087243 (in boys), NFKB1 rs28362491 (in girls) and the haplotype
TNFA rs1800629*A - LTA rs909253*G (in girls).
Conclusion: As a result of the study, the relationship of the alleles/genotypes of the IL1B rs16944, IL10 rs1800872, CTLA4 rs3087243,
NFKB1 rs28362491 polymorphic loci and the TNFA rs1800629*A - LTA rs909253*G haplotype with the methotrexate efficacy in JIA was
established (taking into account the differences by sex).
Key words: Juvenile idiopathic arthritis, polymorphic loci, methotrexate efficacy, predictors

1. Introduction
Juvenile idiopathic arthritis (JIA) is the most common
childhood rheumatic disease, which begins before the
age of 16 and is characterized by arthritis persisting at
least 6 weeks [1–3]. The JIA diagnosis is entirely based on
the clinical features, and the generally accepted disease
classification is the International League of Associations
for Rheumatology (ILAR) classification [1].
Being a chronic, steadily progressive disease, JIA can
lead to short-term and long-term disability [2]. Thus,
early and effective therapy is crucial for preventing JIA
complications and patients’ disability [3–7].

Methotrexate is the most widely used disease-modifying
antirheumatic drug in the JIA treatment [4]. Methotrexate
was first described as the antimetabolite of folic acid and
was used in the field of oncology, but the mechanism of its
action in rheumatology is still poorly understood [8]. The
antiinflammatory effects of methotrexate in JIA may be
mediated by addition to folate antagonism mechanisms,
such as adenosine release, inhibition of spermine/
spermidine production and/or alteration of cellular
redox state [9]. It has been shown that methotrexate may
directly or indirectly affect the expression and/or secretion
of the various immune response mediators involved in
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the pathogenesis of JIA and other autoimmune diseases,
including cytokines (such as tumour necrosis factor alpha
(TNFα), interleukin 1 (IL1), IL2, IL6, IL10), nuclear factor
kappa B (NFκB), cytotoxic T-lymphocyte associated
protein 4 (CTLA4) and others [10–13].
Nevertheless, the response to therapy varies among
the JIA patients, and the identifying of early predictors
of the methotrexate efficacy is highly relevant [4,7].
Currently, a search for the genetic predictors of the
methotrexate efficacy in JIA is underway. The most
promising are polymorphic variants of genes involved
in the methotrexate metabolic pathway or genes, whose
expression changes under the methotrexate effect, as well
as a number of markers identified in the genome-wide
association study (GWAS) [4,9,14–16]. In addition, the
relationship can be assumed between the methotrexate
efficacy and the polymorphic variants of other genes
encoding proteins, presumably playing an important
role in the JIA pathogenesis, including interleukin 2
receptor subunit alpha (IL2Rα), lymphotoxin alpha (LTα),
macrophage migration inhibitory factor (MIF), protein
tyrosine phosphatase nonreceptor type 22 (PTPN22),
peptidyl arginine deiminase 4 (PADI4) [17–19].
Considering what is mentioned above, the search
for the predictors of the JIA patients’ response to
methotrexate among some polymorphic variants of genes,
whose products are involved in the pathogenesis of the
autoimmune diseases and are the potential targets for the
methotrexate exposure, seems appropriate. Identification
of these markers may provide an opportunity to timely
predict the JIA therapy efficacy, to determine an adequate
treatment strategy, and to prevent the development of the
disease complications [3–7]. Thus, the aim of the study
was to analyze the relationship of the immune response
mediator genes polymorphic loci (TNFA rs1800629,
LTA rs909253, IL1B rs16944, IL2-IL21 rs6822844,
IL2RA rs2104286, IL6 rs1800795, IL10 rs1800872,
MIF rs755622, CTLA4 rs3087243, NFKB1 rs28362491,
PTPN22 rs2476601, PADI4 rs2240336) variants with the
methotrexate efficacy in JIA.
2. Materials and methods
2.1. Study design and subjects
A case-control study was conducted. The study was
approved by the expert council on biomedical ethics of
Bashkir State Medical University (Ufa, Russia).
The study included 274 JIA patients treated with
methotrexate. Parents of all patients signed the voluntary
informed consent. All patients were residents of the
Republic of Bashkortostan and were examined and
treated in the cardio-rheumatological department of the
Republican Children’s Clinical Hospital (Ufa, Russia) in
2011–2017. The median age of the patients was 8.69 (4.82;

12.80) years; the ratio of boys/girls was 31.75%/68.25%.
The JIA diagnosis was established according to the
International League of Associations for Rheumatology
(ILAR) criteria [1]. According to the ILAR criteria, the
following JIA subtypes were presented: systemic arthritis
(n = 25 (9.12%)), rheumatoid factor positive polyarthritis
(n = 5 (1.82%)), rheumatoid factor negative polyarthritis (n
= 76 (27.74%)), persistent oligoarthritis (n = 77 (28.10%)),
extended oligoarthritis (n = 41 (14.96%)), enthesitis
related arthritis (n = 26 (9.49%)), psoriatic arthritis (n = 8
(2.92%)), undifferentiated arthritis (n = 16 (5.84%)).
Achieving the American College of Rheumatology
Pediatric 30 (ACR Pedi 30) response was regarded as the
presence of the response to methotrexate (otherwise, as the
absence), while achieving clinical remission on medication
(Wallace et al., 2011) - as the sufficient response (otherwise,
as the insufficient) [5,20–22]. Evaluation of the presence of
the response to methotrexate was performed in patients
who received the therapy for at least 3 months, and the
sufficiency of the response was evaluated in patients who
received the therapy for at least 12 months.
2.2. Genotyping
DNA isolation from the lymphocytes of the whole
blood samples was performed using a standard phenolchloroform method [23]. Genotyping of all the patients for
the 12 polymorphic loci (TNFA rs1800629, LTA rs909253,
IL1B rs16944, IL2-IL21 rs6822844, IL2RA rs2104286,
IL6 rs1800795, IL10 rs1800872, MIF rs755622, CTLA4
rs3087243, NFKB1 rs28362491, PTPN22 rs2476601, PADI4
rs2240336) was conducted by the real-time polymerase
chain reaction (StepOnePlus™ Real-Time PCR System,
Applied Biosystems, USA). Sequence-specific primers and
allele-specific probes were designed and synthesized by
the “DNK-syntez” company (Russia).
2.3. Statistical analysis
Statistical processing of the results was carried out using
Microsoft Excel, SNPStats, R v.3.4.2 (R Core Team, 2017),
PowerMarker v.3.25, STATISTICA v.10 (StatSoft, Inc.)
[24–26].
To compare the genotype and allele frequencies in the
studied groups the two-tailed Fisher’s exact test was used.
A similar analysis was also performed separately for boys
and girls. The multiple testing correction of the P-values
was carried out by applying the permutation test with
104 permutes (pcor) [24,27]. The odds ratio (OR) with the
Baptista–Pike exact conditional 95% confidence interval
(95% CI) were also calculated [28].
The haplotypes of the TNFA rs1800629 and LTA
rs909253 polymorphic loci, located in the same cluster
on chromosome 6, have also been studied as the potential
predictors of the methotrexate efficacy in JIA, since the
linkage disequilibrium for these loci was almost complete
(D’ = 0.9989, P = 0.000). The association between the
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TNFA rs1800629 - LTA rs909253 loci haplotypes and the
methotrexate efficacy in JIA was analyzed using the logistic
regression method [25].
The analysis of the inheritance models (codominant,
each genotype can give a different and nonadditive
risk; dominant, one copy of the variant allele is enough
to change the risk; recessive, two copies of the variant
allele are necessary to change the risk; overdominant,
heterozygous genotype is compared to a pool of both
homozygous genotypes; log-additive, each copy of the
variant allele changes the risk in an additive form) was
carried out using the logistic regression method, and the
selection of the best one - using the Akaike’s Information
Criterion. The inheritance model with the lowest Akaike’s
Information Criterion value was considered as the model
that best fits the data [25].
In all the cases the results were considered statistically
significant at P < 0.05.
3. Results
3.1. The study of the predisposition to the absence of the
response to methotrexate in JIA
When studying the IL10 rs1800872 polymorphic locus, no
predictors of the absence of the response to methotrexate
were found in the whole JIA group, as well as in boys
with JIA (P > 0.1) (Table 1). At the same time, in girls
with JIA, the frequency of the IL10 rs1800872*A allele
was significantly higher, and of the IL10 rs1800872*CС
genotype – significantly lower in the absence of the
response to methotrexate than in its presence (*A: 38.16%
vs. 24.81%, P = 0.029, pcor = 0.027, OR = 1.87, 95% CI
1.069–3.162; *CC: 36.84% vs. 57.36%, P = 0.028, pcor =
0.029, OR = 0.434, 95% CI 0.215–0.932, respectively). The
dominant model of inheritance reflected the results better
than the others (CA+AA vs. CC, P = 0.026).
Analysis of the NFKB1 rs28362491 polymorphic locus
showed that the NFKB1 rs28362491*DD genotype was
significantly more common, and the NFKB1 rs28362491*I
allele was significantly less common in JIA patients with
the absence of the response to methotrexate than in those
with its presence (*DD: 31.03% vs. 13.26%, P = 0.005,
pcor = 0.004, OR = 2.944, 95% CI 1.484–5.938; *I: 48.28%
vs. 59.94%, P = 0.031, pcor = 0.033, OR = 0.624, 95% CI
0.410–0.944, respectively). After stratification based on
the sex of the patients, similar significant differences for
the NFKB1 rs28362491*DD genotype were found only in
girls with JIA (P = 0.017, pcor = 0.017, OR = 2.846, 95%
CI 1.253–6.483), and only a similar trend was observed in
boys with JIA (pcor = 0.085), which is probably due to the
smaller sample size. The best inheritance model turned out
to be the recessive (DD vs. II+ID, P = 0.0032 and P = 0.018
in JIA as a whole and in girls, respectively).
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For the alleles and genotypes of the TNFA rs1800629,
LTA rs909253, IL1B rs16944, IL2-IL21 rs6822844,
IL2RA rs2104286, IL6 rs1800795, MIF rs755622, CTLA4
rs3087243, PTPN22 rs2476601, PADI4 rs2240336
polymorphic loci, as well as haplotypes of the TNFA
rs1800629 - LTA rs909253 loci, no associations were
observed with the considered trait (P > 0.05).
When studying the PADI4 rs2240336 polymorphic
locus, a borderline significance level tendency was
observed for the increase of the proportion of the PADI4
rs2240336*GA genotype and the decrease of the proportion
of the PADI4 rs2240336*GG genotype in JIA patients with
the absence of the response to methotrexate (*GA: pcor =
0.053 and *GG: pcor = 0.053, respectively). However, the
significant results were obtained for the dominant model
as the best model of inheritance (GA+AA vs. GG, P =
0.032). In the similar sex-stratified analysis, a tendency
was observed in boys with JIA for the rarer occurrence
of the PADI4 rs2240336*GG genotype in the case of the
absence of the response to methotrexate (pcor = 0.091).
It was also noted that in the case of the absence of the
response to methotrexate in patients with JIA, the IL2IL21 rs6822844*TT and LTA rs909253*AG genotypes were
nonsignificantly more common (IL2-IL21 rs6822844*TT:
pcor = 0.054, LTA rs909253*AG: pcor = 0.098), and the
statistically significant results were obtained for the IL2IL21 rs6822844 locus when testing the recessive model of
inheritance (TT vs. GG+GT, P = 0.017).
3.2. The study of the predisposition to the insufficient
response to methotrexate in JIA
Analysis of the IL1B rs16944 polymorphic locus showed
a tendency towards a rarer occurrence of the IL1B
rs16944*CC genotype in JIA patients with the insufficient
response to methotrexate than in those with the sufficient
(37.88% vs. 50.00%, respectively, pcor = 0.094) (Table 2).
After stratification by sex, it turned out that boys with JIA,
who did not achieve clinical remission on medication with
the methotrexate therapy, had a significantly increased
proportion of the IL1B rs16944*T allele (41.86% vs. 22.00%,
P = 0.025, pcor = 0.024, OR = 2.553, 95% CI 1.195–5.410,
in comparison with those who achieved, respectively).
The log-additive model of inheritance reflected the results
most successfully (2TT+CT vs. CC, P = 0.036). At the
same time, there were no significant differences by the
studied trait in girls with JIA (P > 0.1).
For the alleles and genotypes of the CTLA4 rs3087243
locus, associations with the insufficient response to
methotrexate in the general JIA group and in girls with
JIA have not been established (P > 0.1). At the same
time, in boys with JIA with the insufficient response to
methotrexate the CTLA4 rs3087243*GA genotype and
the CTLA4 rs3087243*A allele were significantly more
common, and the CTLA4 rs3087243*GG genotype was

G/A

G/A

909253

16944

6822844

2104286

1800795

1800872

755622

3087243

28362491

LTA

IL1B

IL2-21

IL2RA

IL6

IL10

MIF

CTLA4

NFKB1

PTPN22 2476601

PADI4

G/A

G/C

C/A

G/C

A/G

G/T

C/T

A/G

G/A

(11)/(12)/(22)

84.5/15.5/0.0

77.3/22.1/0.6

36.2/55.2/8.6

46.4/42.5/11.0

36.2/46.6/17.2

41.4/44.2/14.4

81.0/15.5/3.4

84.0/16.0/0.0

74.1/22.4/3.4

69.6/27.6/2.8

36.2/53.4/10.3

38.7/47.0/14.4

43.1/41.4/15.5

52.5/37.6/9.9

67.2/31.0/1.7

64.1/32.0/3.9

50.0/41.4/8.6

47.0/40.9/12.2

27.6/41.4/31.0

33.1/53.6/13.3

74.1/22.4/3.4

75.7/22.7/1.7

20.7/62.1/17.2

35.4/47.0/17.7

(2)

7.8

11.6

36.2

32.3

40.5

36.5

11.2

8.0

14.7

16.6

37.1

37.8

36.2

28.7

17.2

19.9

29.3

32.6

51.7

40.1

14.7

13.0

48.3

41.2

absence of response
presence of response

NS

NS

NS

NS

NS
2.10
1.04-4.24

NS
dom
0.032
§

rec
2.94
0.0032 1.46-5.94

NS

NS

NS

NS

NS

NS

NA
0.00-NA

rec
0.017
§

NS

NS

NS

OR
95% CI

NS

NS

NS

var
p

34.9/46.5/18.6

23.7/57.9/18.4

47.4
41.9

73.6/24.8/1.6

76.3/18.4/5.3

31.8/54.3/14.0

28.9/39.5/31.6

42.6/45.0/12.4

57.9/34.2/7.9

62.8/34.1/3.1

71.1/26.3/2.6

57.4/35.7/7.0

36.8/50.0/13.2

36.4/51.2/12.4

34.2/60.5/5.3

69.0/27.9/3.1

73.7/23.7/2.6

14.0

14.5

41.1

51.3

34.9

25.0

20.2

15.8

24.8

38.2

38.0

35.5

17.1

14.5

82.2/17.8/0.0

81.6/15.8/2.6

10.5
8.9

38.8/47.3/14.0

34.2/52.6/13.2

47.3/42.6/10.1

39.5/50.0/10.5

77.5/22.5/0.0

84.2/15.8/0.0

(11)/(12)/(22)

37.6

39.5

31.4

35.5

11.2

7.9

(2)

absence of response
presence of response

Аlleles and genotypes
frequencies, %

Аlleles and genotypes
frequencies, %

Model of
inheritance

Female (f)

The whole group (f+m)

NS

NS

rec
0.018

NS

NS

dom
0.026

NS

NS

NS

NS

NS

-

var
p

37.5

40.0

15.4

15.0

5.8

12.5

33.7

42.5

34.6

37.5

12.5

7.5

(2)

NS

NS

39.4

50.0

10.6

15.0

52.5

26.9

37.5

19.2

20.0

2.85
1.22-6.63 37.5

NS

NS

36.5/48.1/15.4

15.0/70.0/15.0

80.8/17.3/1.9

70.0/30.0/0.0

36.5/51.9/11.5

25.0/45.0/30.0

57.7/30.8/11.5

35.0/55.0/10.0

67.3/26.9/5.8

60.0/40.0/0.0

40.4/42.3/17.3

55.0/25.0/20.0

44.2/36.5/19.2

40.0/40.0/20.0

71.2/26.9/1.9

75.0/20.0/5.0

88.5/11.5/0.0

80.0/15.0/5.0

48.1/36.5/15.4

40.0/35.0/25.0

44.2/42.3/13.5

30.0/65.0/5.0

76.9/21.2/1.9

85.0/15.0/0.0

(11)/(12)/(22)

absence of response
presence of response

Аlleles and genotypes
frequencies, %

32.5
2.31
1.09-4.86 38.5

NS

NS

NS

NS

NS

-

OR
95% CI

Model of
inheritance

Male (m)

NS

NS

NS

NS

NS

NS

NS

NS

NS

NS

NS

NS

var
p

NS

NS

NS

NS

NS

NS

NS

NS

NS

NS

NS

NS

OR
95% CI

Model of
inheritance

181 : 129 : 52

58 : 38 : 20

181 : 129 : 52

58 : 38 : 20

181 : 129 : 52

58 : 38 : 20

181 : 129 : 52

58 : 38 : 20

181 : 129 : 52

58 : 38 : 20

181 : 129 : 52

58 : 38 : 20

181 : 129 : 52

58 : 38 : 20

181 : 129 : 52

58 : 38 : 20

181 : 129 : 52

58 : 38 : 20

181 : 129 : 52

58 : 38 : 20

181 : 129 : 52

58 : 38 : 20

181 : 129 : 52

58 : 38 : 20

f+m : f : m

absence of response
presence of response

The total number of
genotyped subjects, ni

ni

Note: (1) – the major allele, (2) – the minor allele; (11) and (22) – genotypes homozygous for the major and minor alleles, respectively; (12) – heterozygous genotype; f+m – female
and male, f – female, m – male; Model of inheritance – the best model of inheritance (regression analysis): var – type of the model: dom – dominant: (12)+(22) vs (11); rec –
recessive: (22) vs (12)+(11); statistically significant results are highlighted in bold; the § symbol indicates models, the differences in which did not reach the statistical significance
level in the analysis using the two-tailed Fisher’s exact test; NS – statistically nonsignificant; NA – not available.

2240336

I/D

1800629

(1)/(2)

TNFA

Alleles

rs

Genes

Polymorphic loci

Table 1. The relationship of the polymorphic loci alleles and genotypes with the absence of the response to methotrexate in JIA patients.
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1800629

909253

16944

6822844

2104286

1800795

1800872

755622

3087243

28362491 I/D

2476601

2240336

LTA

IL1B

IL2-21

IL2RA

IL6

IL10

MIF

CTLA4

NFKB1

PTPN22

PADI4

(11)/(12)/(22)

85.6/14.4/0.0

76.3/23.8/0.0

50.8/43.2/6.1

45.0/45.0/10.0

37.9/44.7/17.4

50.0/36.3/13.8

83.3/14.4/2.3

83.8/16.3/0.0

73.5/22.0/4.5

67.5/28.8/3.8

33.3/53.0/13.6

38.8/42.5/18.8

50.8/38.6/10.6

52.5/38.8/8.8

67.4/29.5/3.0

63.8/28.8/7.5

44.7/44.7/10.6

56.3/35.0/8.8

33.3/38.6/28.0

25.0/62.5/12.5

77.3/20.5/2.3

73.8/23.8/2.5

29.5/54.5/15.9

40.0/43.8/16.3

(2)

7.2

11.9

27.7

32.5

39.8

31.9

9.5

8.1

15.5

18.1

40.2

40.0

29.9

28.1

17.8

21.9

33.0

26.3

47.3

43.8

12.5

14.4

43.2

38.1

insufficient response
sufficient response

NS

NS

over-d
0.0007

NS

NS

NS

NS

NS

NS

NS

NS

-

var
p

NS

NS

41.8

43.3

15.5

12.9

46.6

29.1

30.3

21.8

14.6

24.5

31.5

40.0

41.0

18.2

17.4

10.0

7.9

36.4

38.8

34.5

25.3

13.6

7.3

(2)

36.4/43.6/20.0

30.3/52.8/16.9

70.9/27.3/1.8

77.5/19.1/3.4

23.6/65.5/10.9

33.7/39.3/27.0

50.9/40.0/9.1

49.4/40.4/10.1

61.8/32.7/5.5

71.9/27.0/1.1

56.4/38.2/5.5

47.2/42.7/10.1

36.4/47.3/16.4

29.2/59.6/11.2

67.3/29.1/3.6

70.8/23.6/5.6

80.0/20.0/0.0

85.4/13.5/1.1

43.6/40.0/16.4

36.0/50.6/13.5

41.8/47.3/10.9

55.1/39.3/5.6

72.7/27.3/0.0

85.4/14.6/0.0

(11)/(12)/(22)

insufficient response
sufficient response

0.38
0.21-0.67 43.6

NS

NS

NS

NS

NS

NS

NS

NS

-

OR
95% CI

Аlleles and genotypes
frequencies, %

Аlleles and genotypes
frequencies, %

Model of
inheritance

Female (f)

The whole group (f+m)

NS

NS

over-d
0.0022

NS

NS

NS

NS

NS

NS

NS

NS

-

var
p

NS

NS

30.0

43.0

12.0

11.6

48.8

20.0

38.4

22.0

24.4

36.0

26.7

40.0

38.4

18.0

11.6

4.0

12.8

22.0

41.9

28.0

32.6

8.0

7.0

(2)

48.0/44.0/8.0

27.9/58.1/14.0

80.0/16.0/4.0

76.7/23.3/0.0

28.0/56.0/16.0

32.6/37.2/30.2

68.0/24.0/8.0

34.9/53.5/11.6

68.0/20.0/12.0

58.1/34.9/7.0

44.0/40.0/16.0

58.1/30.2/11.6

44.0/32.0/24.0

41.9/39.5/18.6

68.0/28.0/4.0

79.1/18.6/2.3

92.0/8.0/0.0

79.1/16.3/4.7

64.0/28.0/8.0

41.9/32.6/25.6

52.0/40.0/8.0

41.9/51.2/7.0

84.0/16.0/0.0

86.0/14.0/0.0

(11)/(12)/(22)

insufficient response
sufficient response

Аlleles and genotypes
frequencies, %

0.34
0.17-0.69 44.0

NS

NS

NS

NS

NS

NS

NS

NS

-

OR
95% CI

Model of inheritance

Male (m)

NS

NS

NS

NS

NS

2.08
1.01-4.27

NS

-

OR
95% CI

80 : 55 : 25

132 : 89 : 43

80 : 55 : 25

132 : 89 : 43

80 : 55 : 25

132 : 89 : 43

80 : 55 : 25

132 : 89 : 43

80 : 55 : 25

132 : 89 : 43

80 : 55 : 25

132 : 89 : 43

80 : 55 : 25

132 : 89 : 43

80 : 55 : 25

132 : 89 : 43

f+m : f : m

insufficient response
sufficient response

The total number of
genotyped subjects, ni

NS

NS

NS

NS

NS

NS

80 : 55 : 25

132 : 89 : 43

80 : 55 : 25

132 : 89 : 43

80 : 55 : 25

132 : 89 : 43

132 : 89 : 43
dom
3.97
0.0078 1.39-11.32 80 : 55 : 25

NS

NS

NS

NS

NS

log-ad
0.036

NS

-

var
p

Model of inheritance

ni

Note: (1) – the major allele, (2) – the minor allele; (11) and (22) – genotypes homozygous for the major and minor alleles, respectively; (12) – heterozygous genotype; f+m – female
and male, f – female, m – male; Model of inheritance – the best model of inheritance (regression analysis): var – type of the model: dom – dominant: (12)+(22) vs (11); over-d –
over-dominant: (12) vs (11)+(22); log-ad – log-additive: (22)+(22)+(12) vs (11); statistically significant results are highlighted in bold; NS – statistically nonsignificant.

G/A

G/A

G/A

G/C

C/A

G/C

A/G

G/T

C/T

A/G

G/A

(1)/(2)

TNFA

Alleles

rs

Genes

Polymorphic loci

Table 2. The relationship of the polymorphic loci alleles and genotypes with the insufficient response to methotrexate in JIA patients.
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A study of the haplotypes of the TNFA rs1800629 and
LTA rs909253 loci showed a tendency towards a rarer
occurrence of the A-G haplotype in JIA patients with the
insufficient response to methotrexate than in those with
the sufficient (7.20% vs. 11.87%, respectively, P = 0.082).
In the similar sex-stratified analysis, these differences for
the A-G haplotype increased and reached the statistical
significance level, but only in girls with JIA (P = 0.046, OR
= 0.41, 95% CI 0.18–0.98).
For the alleles and genotypes of the IL2-IL21 rs6822844,
IL2RA rs2104286, IL6 rs1800795, IL10 rs1800872, MIF
rs755622, PTPN22 rs2476601, PADI4 rs2240336 loci
associations with the insufficient response to methotrexate
were not observed (P > 0.1).

significantly less common, than in those with the sufficient
response (*GA: 53.49% vs. 24.00%, P = 0.023, pcor = 0.022,
OR = 3.642, 95% CI 1.188–11.379; *A: 38.37% vs. 20.00%,
P = 0.035, pcor = 0.036, OR = 2.491, 95% CI 1.128–5.553;
*GG: 34.88% vs. 68.00%, P = 0.012, pcor = 0.013, OR =
0.252, 95% CI 0.094–0.733, respectively). The dominant
model of inheritance described the results better than the
others (GA+AA vs. GG, P = 0.0078).
Analysis of the NFKB1 rs28362491 polymorphic
locus showed that in JIA patients with the insufficient
response to methotrexate the NFKB1 rs28362491*DD
genotype was significantly more common, and the NFKB1
rs28362491*ID genotype was significantly less common,
than in those with the sufficient response (*DD: 28.03% vs.
12.50%, P = 0.010, pcor = 0.011, OR = 2.726, 95% CI 1.306–
5.568; *ID: 38.64% vs. 62.50%, P = 0.001, pcor = 0.0008, OR
= 0.378, 95% CI 0.213–0.675, respectively). However, after
stratification by sex, the same associations were observed
only in girls with JIA (*DD: P = 0.022, pcor = 0.024, OR =
3.015, 95% CI 1.192–7.700; *ID: P = 0.003, pcor = 0.003, OR
= 0.342, 95% CI 0.175–0.672, respectively). The best model
of inheritance turned out to be the overdominant (ID vs.
II+DD, P = 0.0007 and P = 0.0022 in the general JIA group
and in girls with JIA, respectively).
For the separate variants of the TNFA rs1800629 and
LTA rs909253 polymorphic loci, no associations with
the insufficient response to methotrexate in JIA were
found (P > 0.05). There was only a tendency towards an
increase of the TNFA rs1800629*GG genotype proportion
and a decrease of the TNFA rs1800629*GA genotype
proportion in JIA patients who did not achieve clinical
remission on medication with the methotrexate therapy
(pcor = 0.096; the *AA genotype was absent in this sample).
After stratification by sex, a similar trend for the TNFA
rs1800629*GG and *GA genotypes was observed and even
increased only in girls with JIA (pcor = 0.081).

4. Discussion
As a result of the study, the predictors of the methotrexate
efficacy in JIA were established. Associations with an
altered risk of the nonresponse to methotrexate in JIA
were observed for the alleles/genotypes of the loci IL10
rs1800872 (in girls) and NFKB1 rs28362491 (in girls); with
an altered risk of the insufficient response to methotrexate
in JIA - for the alleles/genotypes of the loci IL1B rs16944
(in boys), CTLA4 rs3087243 (in boys), NFKB1 rs28362491
(in girls), and the haplotype TNFA rs1800629*A - LTA
rs909253*G (in girls) (Table 3).
According to the available data, the genetic markers
considered in this work have not been previously studied
for the associations with the methotrexate efficacy in JIA.
It has been shown that the methotrexate treatment
reduces the TNFα, IL1β, and IL6 production and increases
the IL10 expression in the synovial tissue of rheumatoid
arthritis patients [12]. At the same time, Pawlik et al.
(2006) established the interrelation of a number of the
cytokine genes polymorphic loci variants with the level
of phytohemagglutinin-stimulated secretion of the

Table 3. Genetic predictors of the methotrexate efficacy in JIA.
Response to methotrexate
Absent

Insufficient

f+m

f

m

f+m

f

m

TNFA rs1800629 - LTA rs909253 (haplotypes)

-

-

-

-

A-G

-

IL1B rs16944

-

-

-

-

-

T, C

IL10 rs1800872

-

A, C, CC

-

-

-

-

CTLA4 rs3087243

-

-

-

-

-

GA, A, GG, G

NFKB1 rs28362491

DD, D, I

DD

-

DD, ID

DD, ID

-

Note: f+m – female and male; f – female; m – male; alleles and genotypes for which OR > 1 (P < 0.05) are highlighted in
bold; underlined font on a gray background; alleles, genotypes, and haplotype for which OR < 1 (P < 0.05) are italicized.
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corresponding products by peripheral blood mononuclear
cells of healthy volunteers from Poland [10]. In particular,
there was a significant increase of the levels of IL6 in
the IL6 rs1800795*GG homozygotes (in comparison
with the IL6 rs1800795*CC homozygotes), of IL10 – in
homozygotes for the GCC haplotype of the IL10 gene
rs1800896, rs1800871, and rs1800872 loci (compared
to the ATA/ATA, ACC/ACC, ACC/ATA genotypes), of
TNFα – in the TNFA rs1800629*GA heterozygotes (in
comparison with the TNFA rs1800629*GG homozygotes).
The identified differences remained even after the
treatment of the cell culture with increasing doses of
methotrexate, but not dexamethasone [10]. Considering
that IL10 is one of the main antiinflammatory mediators
[11], these data are partially consistent with the results
of the present work, where the association of the
IL10 rs1800872*A allele with an increased risk of the
nonresponse to methotrexate in girls with JIA was shown.
At the same time, TNFα has a powerful proinflammatory
effect [11], but in the present work it was shown that
the TNFA rs1800629*A allele in the TNFA rs1800629*A
- LTA rs909253*G haplotype acts as a protective marker
in relation to the insufficient response to methotrexate in
girls with JIA. This fact may be due to the presence of the
LTA rs909253*G allele, since Pociot et al. (1991) showed
that the levels of the TNFα and IL1β production by
lipopolysaccharide- and phytohemagglutinin-stimulated
monocytes were significantly lower in healthy carriers of
the LTA rs909253*AG genotype than in those with the LTA
rs909253*AA genotype [29]. Given the sexual specificity
of the established association, it can also be assumed that
the observed contradictions are related to the peculiarities
of the immune response regulation in males and females,
leading to the differences in the secretion of cytokines and
other mediators [30].
The data on the relationship of the IL1B rs16944
polymorphic loci variants with the IL1B expression are
extremely contradictory. In particular, analyzing the IL1B
gene haplotypes, Chen et al. (2006) showed the association of
the IL1B rs16944*T allele with an increased transcriptional
activity of the reporter gene when stimulated by
lipopolysaccharide- and phorbol-12-myristate-13-acetate
[31], and Wen et al. (2006) – with a decreased one when
stimulated only by lipopolysaccharide [32]. In addition
to the experimental features, these differences can also be
associated with the samples characteristics, in particular
with the sex ratio, since in the present work it has been
shown that the IL1B rs16944*T allele increases the risk of
the insufficient response to methotrexate only in boys with
JIA. It should also be noted that the relationship of the
IL1B rs16944*TT genotype with the nonachieving of the
ACR Pedi 70 response to etanercept in JIA was previously
established, which is important to consider when selecting
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the second-line therapy for these patients [33].
CTLA4 is a member of the immunoglobulin-related
receptors family and is believed to play an important role
in mediating the suppressive function of regulatory T cells
[34]. Cribbs et al. (2015) showed that the methotrexate
treatment of rheumatoid arthritis patients enhances
the reduced CTLA4 expression in regulatory T cells
and restores their defective suppressor function [13].
Moreover, Kasela et al. (2017) found that the CTLA4
rs3087243*A allele is associated with the higher CTLA4
expression levels in the CD4+ and CD8+ T cells [35]. It can
be assumed that the presence of the CTLA4 rs3087243*A
allele in boys with JIA indicates the predominance of other
pathogenetic mechanisms that are not associated with the
reduced CTLA4 expression, which determines the absence
of the important therapeutic target for the methotrexate
exposure and, as a result, its insufficient efficacy in this
group of patients.
An important role in the regulation of inflammation,
cell survival and proliferation is played by NFκB, a family
of transcription factors (RelA (p65), cRel, RelB, NFκB1
(p50 and its precursor p105), and NFκB2 (p52 and its
precursor p100)), which functions as various heteroor homodimers [12,36,37]. One of the key members of
this family is p50 encoded by the NFKB1 gene. It should
be noted that p50 has opposite effects in the hetero-/
homodimeric forms. Thus, p50/p50 homodimers have
an antiinflammatory effect, inhibiting the transcription
of proinflammatory cytokine genes, including TNFA, and
enhancing the IL10 gene transcription. At the same time,
p50/p65 heterodimers exhibit proinflammatory properties
and stimulate the transcription of the corresponding
cytokine genes, including TNFA [36–38]. Methotrexate
has been shown to inhibit the p65 phosphorylation
and thereby to downregulate the expression of TNFA
[39,40]. It is assumed that the NFKB1 rs28362491*D
allele may cause a decrease in the NFKB1 expression
and, accordingly, the p50 production; the decrease in
the p50/p50 homodimer levels most likely exceeds the
decrease in the p50/p65 heterodimer levels, which leads
to the increased proinflammatory cytokine production
in these patients [37,38,41]. In addition, the decrease
in the p50/p65 heterodimer formation may lead to
the partial loss of an important therapeutic target for
the methotrexate exposure, which overall mediates its
subsequent inefficiency. At the same time, an increased
proinflammatory cytokine production in the NFKB1
rs28362491*D allele carriers may suggests a good effect
of an anticytokine therapy. This hypothesis is confirmed
by the data of Nazarova et al. (2018), according to which
the NFKB1 rs28362491*D allele reduces the risk of
nonachieving the ACR Pedi 70 response to etanercept in
JIA patients [33]. At the same time, in the present work
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it was shown that the NFKB1 rs28362491*DD genotype
marks an increased susceptibility to the nonresponse to
methotrexate in JIA (in girls). These data are of particular
interest in terms of predicting the efficacy of JIA therapy:
they allow to identify the risk group for the nonresponse
to methotrexate and at the first signs of an unfavorable
prognosis realization or initially to recommend the
strengthening of therapy by prescribing etanercept for this
group.
The potential limitations of this research are the
relatively small number of the studied polymorphic
genes variants, as well as the possible ethnic specificity
of the identified associations. To confirm the obtained
data, replicative studies on different ethnicity samples
are required, as well as additional immunological
studies to assess the true causes underlying the observed
associations. In addition, the prediction of the JIA therapy
efficacy using the genetic testing is quite expensive, so
the implementation of this method in low economic
communities may be rather difficult.
This study was aimed to identify the potential predictors
of the JIA patients’ response to methotrexate among some
of the immune response mediator genes’ polymorphic
loci (TNFA rs1800629, LTA rs909253, IL1B rs16944, IL2IL21 rs6822844, IL2RA rs2104286, IL6 rs1800795, IL10
rs1800872, MIF rs755622, CTLA4 rs3087243, NFKB1
rs28362491, PTPN22 rs2476601, PADI4 rs2240336)
variants. As a result of the study, the relationship of the
alleles/genotypes of the IL1B rs16944, IL10 rs1800872,

CTLA4 rs3087243, NFKB1 rs28362491 polymorphic loci
and the TNFA rs1800629*A - LTA rs909253*G haplotype
with the methotrexate efficacy in JIA has been established
(taking into account the differences by sex). Associations
for the IL1B rs16944 and NFKB1 rs28362491 polymorphic
loci variants seem to be the most promising, since they
allow to evaluate the efficacy prognosis simultaneously for
two the most widely used disease-modifying antirheumatic
drugs in the JIA treatment: methotrexate and etanercept. If
confirmed in replicative studies, the established markers
might be used for the early prediction of the JIA therapy
efficacy and the timely appointment of an adequate
medication, which is crucial for preventing the disease
complications.
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